कोशिश गोल्ड - मुक्त

“Covid-19 Highlighted The Limitations Of Our Current Healthcare Infrastructure”

BioSpectrum Asia

|

August 2020

COVID-19 has exposed the inadequacies in the healthcare industry, which is now evolving through vigorous transformation. The Asia Pacific (APAC) region is embracing digital transformation in the healthcare ecosystem. According to a 2020 report by Bain & Company, the APAC region is set to represent more than 40 per cent of growth in global healthcare spending over the next decade, expanding at a rate almost double than that of the rest of the world. This also means that APAC stakeholders have an unprecedented opportunity to transform the region’s healthcare landscape through collaboration and networking tools. Dirk Dumortier, Head of Business Development, Smart City and Healthcare (Asia Pacific) at Alcatel-Lucent Enterprise, Singapore, shared his views with BioSpectrum Asia about the new framework for healthcare delivery. Edited excerpts;

- Hithaishi C Bhaskar

“Covid-19 Highlighted The Limitations Of Our Current Healthcare Infrastructure”

Dirk Dumortier, Head of Business Development SmartCity and Healthcare (APAC region), Alcatel-Lucent Enterprise, Singapore

What does healthcare continuity mean in the times of COVID-19?

There are two aspects to consider in healthcare continuity – operational needs and technical needs.

Operational needs involve ensuring that health facilities like clinics and hospitals remain operating during a pandemic while protecting both patients and healthcare workers. There are multiple ways to go about this. For instance, the building of temporary wards or rearranging normal wards into Intensive Care Units (ICUs) to cater to the surge in demand. Minimizing physical contact between patients and healthcare workers using collaboration tools that allow for shift handovers to be done remotely. Or the use of collaboration tools to enable administrative staff to work from home and general practitioners to reach out to their patients remotely.

Technical needs refer to the technologies that allow healthcare facilities to resolve operational requirements within a short time frame. Hospitals and clinics need to tap on technology that allows for:

Ruggedised network infrastructure to create secure wired and wireless connectivity for both hospital and patient use.

Work from home software and hardware – extending the hospital and care network and communications to home, allowing staff to work remotely without affecting operations.

Over-the-top (OTT) cloud collaboration licenses for free to all healthcare workers. This managed service does not require any onsite installations and can be rolled out quickly, enabling collaboration between hospitals and clinics, and even teleconsultations.

BioSpectrum Asia से और कहानियाँ

BioSpectrum Asia

Repligen introduces next-generation chromatography resins

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India

Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh

\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.

time to read

1 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cartherics names Dr lan Nisbet as CEO

Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Neurophet ropes in Josh Cohen as Head of Americas Business

South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

India's Final Mile to TB Elimination

As the target year 2025 draws to a close, the Government of India has intensified and consolidated nationwide efforts to eliminate tuberculosis (TB) through the TB-Mukt Bharat Abhiyaan, implemented under the National Tuberculosis Elimination Programme (NTEP). India's decision to advance the TB elimination timeline ahead of global targets has driven sustained reforms across detection, treatment, prevention, nutrition support, and community engagement.

time to read

2 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Korea builds AI-engineered nasal spray antiviral platform

A research team at Korea Advanced Institute of Science and Technology has successfully developed a nasal (intranasal) antiviral platform using artificial intelligence (AI) technology to overcome the existing limitations of interferonlambda treatments, namely, being weak against heat and disappearing quickly from the nasal mucosa.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

"Industry needs to evolve and invest in ADC payloads with more differentiated mechanisms of action

Antibody drug conjugates (ADCs) are becoming highly valuable in the market, with currently 15 approved ADCs targeting 16 different indications for haematological and solid tumour malignancies. With key components of ADCs, such as mAbs, linkers, payloads, and conjugation technologies, undergoing rapid advancements, a solid foundation has been laid for future research and development in this field, particularly in North America which is the largest market shareholder for ADCs. US recently wrapped up the world's largest & definitive Antibody-Drug Conjugate event, World ADC, held in November 2025, highlighting the development of novel ADCs through key market players, and a surge in patent application filing for ADCs. Dr Allan Jordan, Vice President of Oncology Drug Discovery at Sygnature Discovery, UK spoke in detail with BioSpectrum Asia about the future outlook of ADCs.

time to read

4 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cytiva and Fida Biosystems collaborate to improve molecular insight for faster drug discovery

Cytiva, a Danaher company and leader in the life sciences industry, and Fida Biosystems, a Danish company specialising in molecular analysis, have joined forces to expand analytical capabilities for protein research.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Excellence Awards Highlight Strength and Future of India's Biotechnology Sector

Former Secretary, Department of Biotechnology (DBT), Government of India, Dr Renu Swarup, underscored the importance of recognising excellence across the biotechnology ecosystem while chairing the jury at the BioSpectrum Excellence Awards.

time to read

1 min

BioSpectrum Asia Jan 2026

Translate

Share

-
+

Change font size